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incidence
In 2006 the estimated age-adjusted annual incidence of breast
cancer in the European Union (25 countries) was 110.3/100 000
and the mortality 25.0/100 000. The incidence is increasing due
to mammographic screening and an ageing population. There
is a steep age gradient with about one-quarter of breast cancers
occurring before age 50, and <5% before age 35. In some
countries the mortality rate has decreased especially in middle-
aged and younger age groups because of improved treatment
and possibly earlier detection. However, breast cancer is still the
leading cause of cancer-related death in European women.
diagnosis
The diagnosis is based on clinical, radiological and pathological
examinations. Clinical examination includes bimanual
palpation of the breasts and local regional lymph nodes.
Radiological examinations include bilateral mammography and
ultrasound of the breasts (and regional lymph nodes depending
on local expertise). MRI of the breast is not needed as a routine
procedure, but may be considered in cases involving diagnostic
challenges arising, e.g. because of dense breast tissue especially
in young women and in cases of familial breast cancer
associated with BRCA mutations, or positive axillary lymph
node status with occult primary tumour in the breast, or where
multiple tumour foci are suspected. Pathological diagnosis
should be based on core needle biopsy obtained by manual, or
preferably by ultrasound or stereotactic guidance. A core needle
biopsy, or if that is not possible, at least a fine needle aspiration
indicating carcinoma should be obtained before any surgical
operation. Final pathological diagnosis should be made
according to the World Health Organization (WHO)
classification and the tumour–node–metastases (TNM) staging
system analysing all tissue removed.
staging and tumour biology assessment
Patient-related staging examinations include complete personal
medical history, family history relating to breast/ovarian and
other cancers, physical examination, performance status, full
blood count, liver and renal function tests, alkaline phosphatase
and calcium. Assessing the menopausal status is imperative [if
in doubt by measuring serum oestradiol and follicle-
stimulating hormone (FSH) levels].
Preoperative disease-related staging includes clinical TNM
staging, pathological examination of the core needle biopsy
with a pathologist’s report on histologic type and grade, and
determination of oestrogen receptor (ER), progesterone
receptor (PgR) and HER2 receptor status by IHC or FISH/
CISH test [III, B]. Alternatively, these markers can be assessed
on the definitive surgical specimen if primary systemic therapy
is not planned.
If preoperative (neoadjuvant) systemic therapy is planned,
additional investigations such as chest X-ray, abdominal
ultrasound and bone scintigraphy should be considered to
exclude metastatic disease. These investigations are
recommended also for patients with locally advanced disease
(clinically positive axillary nodes, large tumours) or clinical
signs, symptoms or laboratory values indicating the presence of
metastases, even if preoperative systemic treatment is not
planned [III, B]. Patients with early stage (e.g. N0) breast
cancer do not profit from comprehensive radiological staging
[III, B].
The postoperative pathological assessment of the surgical
specimen should be made according to the pTNM system to
include: number, location and maximum diameter of tumours
removed, the total number of removed and number of positive
lymph nodes, and the extent of metastases in the lymph nodes
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[isolated tumour cells, micrometastases (0.2–2 mm),
macrometastases]. Sentinel node biopsy is the recommended
procedure for the surgical staging of the axilla for patients with
clinically node-negative (cN0) breast cancer. The report should
also include histological type and grade of the tumour (using
a standard grading system), evaluation of the resection margins
including the location and minimum distance of the margin,
vascular and lymphovascular invasion; immunohistochemical
evaluation of ER and PgR using a standardized assessment
methodology (e.g. Allred or H-score), proliferation markers
such as Ki67 labelling index, and immunohistochemical
evaluation of HER2 receptor expression. HER2 gene
amplification status may be determined directly from all
tumours using in situ hybridization (FISH or CISH), repl2acing
immunohistochemistry (IHC), or only from tumours with an
ambiguous (2+) IHC [II, B].
Clinical parameters have been integrated into scores that
allow the probability of recurrence and death from breast
cancer to be accurately estimated; examples include the
Nottingham prognostic index or Adjuvant
(www.adjuvantonline.com). Gene expression profiles such as
Mammaprint or Oncotype Dx Recurrence Score may be used
to gain additional prognostic and/or predictive information to
complement pathology assessment and to predict response to
adjuvant chemotherapy, in particular in patients with ER-
positive early breast cancer [II, A].
treatment plan
Multidisciplinary treatment planning involving a breast
surgeon, radiologist, pathologist, medical and radiation
oncologists, should be used to integrate local and systemic
therapies and their sequence [III, B]. The possibility of
hereditary cancer should be explored and, if needed,
prophylactic procedures discussed following adequate genetic
counselling and testing of the patient [IV, D].
surgery
Arguably the major change in the surgical treatment of primary
breast cancer has been the shift towards breast conservation
treatment that started over 30 years ago. Currently in western
Europe about two-thirds of newly diagnosed cancers are
amenable to breast conservation (wide local excision and
radiotherapy) but in the remaining third, mastectomy is still
recommended because of tumour size (e.g. >4cm diameter), or
tumour multifocality/multicentricity, prior radiation to the
chest wall or breast.
breast conservation surgery
For patients undergoing wide local excision, greater emphasis is
now placed on achieving acceptable cosmesis and breast
surgeons are now trained to undertake glanduloplasty to reduce
the local volume deficit with adjacent tissue displacement flaps.
Newer oncoplastic procedures such as therapeutic
mammoplasty (breast reduction at the same time as wide local
tumour excision) can achieve better cosmetic outcomes in
patients with large breasts. The role of breast MRI in assessing
tumour multifocality and planning surgery is currently the
subject of intense debate.
Careful histological assessment of resection margins is
essential, and marking the tumour bed with clips can facilitate
accurate siting of the radiation boost field where appropriate.
Postoperative radiotherapy is strongly recommended after
breast conserving surgery [I, A]. Acceptably low local
recurrence rates remain the major quality assurance target and
current guidelines recommend that local recurrence rates after
wide excision and radiotherapy should be <1% per year and
should not exceed 10% overall.
mastectomy
European treatment guidelines recommend that breast
reconstruction should be available to those women requiring
mastectomy. Immediate reconstruction in some women can
make the prospect of losing a breast easier to accept, but not all
women will be suitable for immediate reconstruction. Many
women will decline or defer reconstruction because of personal
preference and for oncological reasons; particularly when post-
mastectomy radiation therapy is anticipated, some women will
be advised against immediate reconstruction. Endoscopic
breast surgery is an emerging technique that is currently being
performed in the context of clinical trials.
For women undergoing breast reconstruction, whether
immediate or delayed, a wide range of surgical options is
available. Silicone gel implants are safe and effective
components of the reconstructive armamentarium [III, A] and
the moratorium against their use in the USA is now over.
Advances in gel cross-linking have reduced silicone bleed and
cohesive gel implants are likely to have fewer problems from
extracapsular rupture.
Myocutaneous tissue flaps using the latissimus dorsi muscle
from the back or transverse rectus abdominis muscle, or the free
deep inferior epigastric perforator (DIEP) flap from the lower
abdomen can replace relatively large volumes of breast tissue.
There is no evidence that reconstruction makes detection of
local recurrence more difficult and no basis for the outdated
view that patients should wait 2 years after mastectomy before
being offered reconstruction.
advances in axillary staging
Regional lymph node status remains the strongest predictor of
long-term prognosis in primary breast cancer. Sentinel lymph
node biopsy (SLNB) rather than full nodal clearance is now
accepted as the standard of care for axillary staging in early
breast cancer [II, A], unless axillary node involvement is
suspected clinically or on ultrasound.
SLNB delivers less morbidity in terms of shoulder stiffness
and arm swelling and allows for reduced hospital stay [I, A].
Training and quality assurance in SLNB have been rolled out to
breast units across Europe in the last 10 years.
The presence of macrometastatic spread in the sentinel node
mandates conventional axillary lymph node clearance. The
optimal management of micrometastatic spread and isolated
tumour cells is the subject of ongoing research.
surgery for in situ malignancy (intraepithelial
neoplasia)
Ductal carcinoma in situ (DCIS, ductal intraepithelial
neoplasia) may be treated with breast-conserving surgery (BCS)
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providing clean healthy tissue margins can be achieved. There is
no general consensus on what is regarded as a safe (negative)
margin, however, margins <2 mm are considered inadequate.
Adjuvant breast irradiation after BCS decreases the risk of local
recurrence but has no effect on survival [I, A]. Total
mastectomy with clear margins in DCIS is curative, and
radiation therapy is not recommended. Lobular neoplasia
(formerly called lobular carcinoma in situ, LCIS), unlike DCIS,
is considered a non-obligate precursor to invasive cancer and is
best regarded as a risk factor for future development of invasive
cancer in both breasts (RR 5.4–12). The pleomorphic variant of
lobular neoplasia may behave similarly to DCIS and should be
treated accordingly.
risk-reducing mastectomy
Risk-reducing surgery with prophylactic mastectomy and
reconstruction may be offered to women at very high risk, such
as those with previous breast cancer or carrying the BRCA1 or
BRCA2 gene mutations, or where invasive carcinoma is
associated with widespread LCIS or hyperplasia with atypia in
the surrounding breast tissue. Risk, both for subsequent breast
cancer incidence and mortality, is reduced by 90%–95% but
prevention of developing breast cancer in the future cannot be
guaranteed [III, A]; careful genetic assessment and
psychological counselling is mandatory before undertaking
such surgery.
The increasing sophistication and knowledge of patients
facing surgery, both for breast cancer treatment and for risk
reduction, mean that the range of surgical options is now
discussed in great depth by breast surgeons, clinicians and
nurses. Despite the overall trend towards breast conservation
over the last 30 years, breast specialists both in Europe and the
USA are noting increasing numbers of younger women opting
for bilateral mastectomy (incorporating contralateral risk-
reducing surgery) in preference to breast conservation and
mammographic surveillance of the irradiated breast.
radiation therapy
invasive carcinoma
Postoperative radiotherapy is strongly recommended after BCS
[I, A]. Whole breast radiotherapy reduces the risk of local
recurrence by two-thirds and an additional boost gives a further
50% risk reduction. Furthermore, radiotherapy has a beneficial
effect on survival. In general, boost irradiation is indicated, too,
in older patients [I, A], but optional in patients with
a presumed low risk of local failure (wide margins, node-
negative, no vessel invasion) [III, B]. In patients >70 years of
age who have endocrine-reponsive invasive breast cancer with
maximum stage pT1N0 and clear margins it may be possible to
omit radiation therapy without compromising survival [II, B].
Partial breast irradiation (PBI) is currently not recommended
outside a clinical trial.
Post-mastectomy radiotherapy is always recommended for
patients with four or more positive axillary nodes [II, B], and
indicated for patients with T3–T4 tumours independent of the
nodal status [III, B]. Post-mastectomy radiotherapy may also
be considered in patients with one to three positive axillary
lymph nodes in the presence of additional risk factors, like
young age, vessel invasion and low number of examined
axillary lymph nodes; the worth of post-mastectomy radiation
therapy in such patients is being investigated in clinical trials.
Randomized trials have used large comprehensive fields
encompassing the chest wall and all regional lymph nodes, but
axillary relapses after axillary dissection and relapses in the
mammary internal region are rare, and irradiation of these sites
is not routinely recommended unless there is suspicious
residual tumour.
Supraclavicular lymph nodes should be considered for
inclusion into the target volume in case of extensive
involvement of axillary and supraclavicular lymph nodes (N ‡
2); internal mammary lymph nodes should be included in the
target volume in cases of metastatic spread to this area.
Adjuvant doses used for local and/or regional irradiation are
45–50 Gy in 25–28 fractions of 1.8–2.0 Gy. The typical boost
dose is 10–16 Gy in 2 Gy single doses. As an option, shorter
fractionation schemes (e.g. 16 fractions with 2.66 Gy single
dose) have shown similar effectiveness and comparable side-
effects [I, B], but caution is needed in young patients, patients
with mastectomy and/or additional regional irradiation, as
these patients were either not included or under-represented in
these trials.
non-invasive carcinoma (intraepithelial neoplasia)
Adjuvant whole breast irradiation after BCS of DCIS decreases
the risk of local recurrence but has no effect on survival [I, A].
Randomized data about additional dose to the tumour bed
(boost) are lacking, but a boost can be considered for patients
at higher risk for local failure, e.g. for young patients [III, B].
PBI only should only be performed within a clinical trial. The
decrease in risk of local recurrence by radiotherapy is evident in
all subtypes of DCIS. However, in some patients with low-risk
DCIS (tumour size <10 mm, low/intermediate nuclear grade,
adequate surgical margins), the risk of local recurrence
following excision only is so low that omitting radiation may be
an option. In ER-positive DCIS tamoxifen may be considered
following BCS (with or without adjuvant radiation) [II, A].
Total mastectomy with clear margins in DCIS is curative, and
radiation therapy is not recommended. In this group of
patients tamoxifen may also be considered to decrease the risk
of contralateral breast cancer [II, B]. Lobular neoplasia
(formerly called LCIS) is a risk factor for future development of
invasive cancer in both breasts; radiotherapy is not warranted.
systemic therapy
primary (neo-adjuvant) systemic therapy
Primary systemic therapy is indicated for locally advanced
breast cancer (stages IIIA–B) including inflammatory breast
cancer [III, B] and for large operable tumours for reducing
tumour size in order to possibly perform BCS [I, A]. Before
primary systemic therapy, a core needle biopsy is essential; in
addition, full clinical staging to rule out gross metastatic
disease. Chemotherapy should be chosen based on predictive
factors similar to adjuvant treatment; primary hormonal
therapy may be useful but has not been investigated in
Annals of Oncology clinical practice guidelines
Volume 21 | Supplement 5 |May 2010 doi:10.1093/annonc/mdq159 | v11
randomized controlled clinical trials. Trastuzumab should be
added to primary chemotherapy in patients with HER2-
positive tumours [II, B]; the concomitant use of anthracyclines
and trastuzumab should be limited to clinical trials. Primary
systemic therapy should be followed by both surgery and
radiation therapy according to the principles outlined above.
Postoperative systemic adjuvant treatment should be used if
appropriate according to the following principles.
adjuvant systemic therapy
Treatment is recommended if a relevant reduction of the
estimated risk of recurrence and death can be expected with an
acceptable level of treatment-related adverse effects. ER and
HER2 status are the most relevant predictive factors for the
choice of treatment modality. Tumours with any detectable
(‡1%) expression of ER and/or PgR are considered endocrine
responsive. Tumours with no detectable expression of ER and
PgR are considered endocrine non-responsive. Features
indicative of uncertainty of endocrine responsiveness include
low levels of steroid hormone receptor immunoreactivity, lack
of PgR, poor differentiation (G3), high proliferation markers
(Ki-67), HER2 overexpression and gene expression scores
(e.g. Oncotype Dx, Mammaprint).
Patients with tumours of different degrees of endocrine
responsiveness may receive endocrine treatment alone, or
a combination of chemotherapy and endocrine therapy, the
choice being determined by factors outlined in Table 1. Patients
with tumours of uncertain endocrine responsiveness are usually
treated with a combination of endocrine therapy and
chemotherapy.
Patients with endocrine non-responsive tumours benefit
from chemotherapy and should not receive endocrine therapy.
In addition to endocrine and chemotherapy, patients with
tumours indicative of HER2 overexpression or amplification
should be considered for adjuvant treatment with trastuzumab
and chemotherapy (see below). For each individual, the choice
of adjuvant therapy must take into account the potential
benefit, possible side-effects and patient preference. Several
decision-making tools have been developed to help doctor–
patient communication for adjuvant treatment decisions.
endocrine therapy
Patients with tumours considered of high or uncertain
responsiveness (ER ‡ 1%) should be treated with endocrine
therapy.
In premenopausal patients tamoxifen alone (20 mg daily for
5 years) or the combination of ovarian function ablation with
tamoxifen are standard therapies. Ovarian function ablation
may be achieved by bilateral oophorectomy which leads to
irreversible ablation of ovarian function. Gonadotropin
releasing hormone analogues (GnRHAs) lead to reversible
ovarian suppression sufficient for therapeutic activity. GnRHAs
should be given for at least 2 years, although optimal duration
for this treatment has not been established [III, D]. Combining
GnRHAs and aromatase inhibitors (AIs) in premenopausal
patients is not indicated, as is the use of AIs alone. Tamoxifen
should not be used simultaneously with chemotherapy, whereas
the best use of GnRHAs (concurrent or sequential with
chemotherapy) is unknown.
In postmenopausal patients AIs are preferably used upfront
for 5 years [I, A]. For patients who are being treated with
tamoxifen a switch to an AI after 2–3 years of tamoxifen is
recommended [I, A]. In postmenopausal patients 5 years of
tamoxifen alone is still a viable option for certain patients at
Table 1. Threshold for treatment modalities according to the 2009 St Gallen Consensus Conference
Relative indications for
chemoendocrine therapy
Factors not useful for
decision
Relative indications for
endocrine therapy alone
Clinicopathological features
ER and PgR Lower ER and PgR level Higher ER and PgR level
Histological grade 3 2 1
Proliferation Higha Intermediatea Lowa
Nodes Node positive (‡4 involved
nodes)
Node positive (1–3 involved
nodes)
Node negative
PVI Presence of extensive PVI Absence of extensive PVI
pT size >5 cm 2.1–5 cm £2 cm
Patient preference Use all available treatments Avoid chemotherapy-related
side-effects
Multigene assays
Gene signatureb High score Intermediate score Low score
(Ann Oncol 2009, with permission).
aConventional measurements of proliferation include assessment of Ki67 labelling index (e.g. low, £15%; intermediate, 16%–30%; high, >30%) and
pathological description of the frequency of mitoses. The reliability of these measurements will vary in different geographical settings. First-generation genetic
signatures contain genes sampling the ER, HER2 and proliferative pathways. Meta-analysis indicates that much of the prognostic information in these
signatures resides in their sampling of proliferative genes, but their respective total scores may be the only form in which information is provided at present
and could be used in this component of assessment of relative indications for chemotherapy.
bThe Panel agreed that validated multigene tests, if readily available, could assist in deciding whether to add chemotherapy in cases where its use was
uncertain after consideration of conventional markers.
ER, oestrogen receptor; PgR, progesterone receptor; PVI, peritumoural vascular invasion.
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very low risk of recurrence. For patients who have completed 5
years of tamoxifen the addition of an AI for a further period of
2–5 years may be recommended especially in cases with node-
positive disease [I, A]. The total duration of optimal adjuvant
endocrine treatment is between 5 and 10 years. Sequential
rather than concurrent administration of cytotoxic and
endocrine therapies should be used [II, A] although it is unclear
whether AIs may be started concurrently with chemotherapy or
sequentially after chemotherapy.
bisphosphonate therapy. Women treated with AIs should
receive sufficient vitamin D and calcium, if necessary as
nutritional supplements; further, a dual energy X-ray
absorption (DEXA) scan is recommended to allow early
treatment of osteoporosis. A DEXA scan should also be
performed for women experiencing premature menopause
(e.g. <45 years of age).
Bisphosphonates prevent bone loss in patients with
iatrogenic premature menopause and in postmenopausal
patients treated with AIs [I, A].
Preliminary data indicate that adjuvant therapy with
zoledronic acid and possibly other bisphosphonates may lower
the risks of breast cancer recurrence in premenopausal patients
treated with endocrine therapy and in postmenopausal patients
treated with AIs. For patients who meet these selection criteria
the use of adjuvant zoledronic acid may be justified [II, B].
There are no data supporting zoledronic acid for patients with
ER-negative tumours or following chemotherapy.
chemotherapy. Adjuvant chemotherapy is recommended for
patients with tumours of uncertain or absent endocrine
responsiveness and for patients with HER2 overexpressing or
amplified tumours. A multiplicity of chemotherapy regimens
acceptable for adjuvant treatment exist (common examples are
listed in Table 2). At present, the use of anthracyclines may be
recommended for most patients and especially for patients with
HER2-positive disease. However, anthracycline-free regimens
with similar or superior efficacy to anthracycline-containing
comparator regimens are being developed (e.g. DC). For some
patients (elderly, cardiac contraindication, etc.), CMF may still
be appropriate [I, A]. Some retrospective analyses suggest that
taxanes may be particularly effective in patients with ER-
negative or HER2-positive early breast cancer; other trials did
not replicate these findings [II, C]. The optimal duration of the
treatment is not known. However, at least four cycles (12–16
weeks) should be administered, generally aiming for six to eight
cycles (18–24 weeks), in particular for patients with a higher
risk of recurrence (e.g. node-positive disease). The use of dose-
dense schedules with prophylactic G-CSF is controversial [II,
B], whilst high-dose therapy requiring bone marrow progenitor
cell support cannot be recommended at all.
trastuzumab. Patients with cancers that overexpress HER2
protein (p185HER2, measured by IHC, e.g. 3+ using HercepTest
DAKO) or have HER2 gene amplification (measured by FISH
or CISH) benefit from adjuvant treatment with trastuzumab [I,
A]. While randomized trials have excluded patients with small
primaries of <1 cm, overexpression of HER2 confers a poor
prognosis, and the use of trastuzumab should be discussed with
women with small, node-negative breast cancers. Based on
pharmacokinetic analyses a 3-weekly schedule (6 mg/kg) is
considered equivalent to a weekly schedule (2 mg/kg). The
optimum duration of adjuvant trastuzumab has not yet been
established but for the time being 1 year is recommended.
Trastuzumab may be started in parallel with a taxane, but it
should not be given concurrently with an anthracycline outside
the context of a clinical trial. Even when given after an
anthracycline-containing regimen trastuzumab may have
cardiotoxic effects and cardiac function should be routinely
monitored. It is important to avoid trastuzumab in patients
with low left ventricular ejection fraction (LVEF, <50%–55%)
and in patients whose cardiac function deteriorates during
therapy. The use of trastuzumab with endocrine therapy
without chemotherapy is not supported by clinical trial
evidence.
follow-up and survivor care
There is no evidence from randomized trials supporting any
particular follow-up sequence or protocol. The aims of follow-
up are to detect early in-breast and local recurrences or
contralateral breast cancer, to evaluate and treat therapy-related
complications (such as menopausal symptoms and
osteoporosis), and to provide psychological support and
information in order to enhance returning to normal life after
breast cancer. Whatever the follow-up protocol and the
frequency of visits, every visit should include history taking,
eliciting of symptoms and physical examination. Ipsilateral
(after BCS) and contralateral clinical mammography is
recommended yearly for premenopausal women and every 1–2
years for postmenopausal women [D]. In asymptomatic
patients, there are no data to indicate that other laboratory or
imaging tests (e.g. blood counts, routine chemistry tests, chest
X-rays, bone scans, liver ultrasound exams, CT scans or any
tumour markers such as CA 15-3 or CEA) produces a survival
benefit [I, A].
Weight gain affect prognosis adversely and should be
discouraged; if necessary, nutritional counselling is
recommended. Regular long-term moderate to strenuous
Table 2.
Regimen No. of cycles Duration of cycles
(weeks)
AC 4 3
CMF 6 4
FEC100 6 3
CEF 6 4
A(or E)/CMF 4/4 (–8) 3/4
AP/CMF 4/4 3/4
DC 4 3
AC/P qwk 4/4 3/3
AC/D 4/4 3/3
ddAC/ddP (G-CSF) 4/4 2/2
DAC 6 3
FEC100/D 3/3 3/3
A, doxorubicin; C, cyclophosphamide; D, docetaxel; E, epirubicin; F,
fluorouracil; G-CSF, granulocyte colony stimulating factor, e.g. filgrastim;
M, methotrexate; P, paclitaxel; qwk, weekly; dd, dose-dense;/, followed
by.
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physical activity is associated with a favourable prognosis;
aerobic training and weight lifting does not negatively affect the
development of lymphoedema.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the experts and the ESMO
faculty.
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